CTOs on the Move

Regado Biosciences

www.regadobio.com

 
Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary ...
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.regadobio.com
  • 120 Mountain View Boulevard
    Basking Ridge, NJ USA 07920
  • Phone: 908.580.2100

Executives

Name Title Contact Details

Similar Companies

Synecor

Synecor is a Chapel Hill, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Stallergenes

Stallergenes is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gene Link Inc

Gene Link Inc is a Hawthorne, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gotham Therapeutics

Gotham Therapeutics has assembled an exceptional team and network to establish a novel drug class targeting RNA-modifying proteins.

Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient`s unique cancer. The company`s clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas, provide a comprehensive genomic profile to identify the molecular alterations in a patient`s cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine`s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.